Rigel Pharmaceuticals
- Country
- 🇮🇳India
- Ownership
- -
- Employees
- 147
- Market Cap
- -
- Introduction
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
Pilot Study of Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)
- Conditions
- Interventions
- First Posted Date
- 2008-06-27
- Last Posted Date
- 2016-06-03
- Lead Sponsor
- Rigel Pharmaceuticals
- Target Recruit Count
- 18
- Registration Number
- NCT00706342
- Locations
- 🇺🇸
Research Site, Cleveland, Ohio, United States
Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis (Taski-3)
- Conditions
- Interventions
- First Posted Date
- 2008-04-24
- Last Posted Date
- 2017-05-01
- Lead Sponsor
- Rigel Pharmaceuticals
- Target Recruit Count
- 219
- Registration Number
- NCT00665626
- Locations
- 🇺🇸
RASF-Clinical Research Center, Boca Raton, Florida, United States
🇺🇸The Osteoporosis & Clinical Trials Center, Hagerstown, Maryland, United States
🇺🇸Desert Medical Advances, Palm Desert, California, United States
Efficacy and Safety Study of R935788 Tablets to Treat Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2008-04-24
- Last Posted Date
- 2016-09-16
- Lead Sponsor
- Rigel Pharmaceuticals
- Target Recruit Count
- 457
- Registration Number
- NCT00665925
- Locations
- 🇺🇸
North Carolina Arthritis & Allergy Care Center, Raleigh, North Carolina, United States
🇧🇬DCC "Sv. Anna" Sofia, Sofia, Bulgaria
🇨🇴Unidad Medica Torre Plaza, MedellÃn, Antioquia, Colombia
Efficacy and Safety Study of Fostamatinib Tablets to Treat B-cell Lymphoma
- First Posted Date
- 2007-03-12
- Last Posted Date
- 2016-09-19
- Lead Sponsor
- Rigel Pharmaceuticals
- Target Recruit Count
- 81
- Registration Number
- NCT00446095
- Locations
- 🇺🇸
Research Site, Cleveland, Ohio, United States
Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1)
- First Posted Date
- 2006-05-16
- Last Posted Date
- 2009-04-20
- Lead Sponsor
- Rigel Pharmaceuticals
- Target Recruit Count
- 189
- Registration Number
- NCT00326339
- Locations
- 🇲🇽
Hospital Civil de Guadalajara "Dr. Juan I. Menchaca", Guadalajara, JA, Mexico
🇲🇽Arke Estudios Clinicos, S.A. de C.V., Ciudad Mexico, DF, Mexico
🇲🇽Centro Médico DALINDE, Mexico, Distrito Federal, Mexico
7 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic Seasonal Allergic Rhinitis
- Conditions
- First Posted Date
- 2005-06-21
- Last Posted Date
- 2005-11-11
- Lead Sponsor
- Rigel Pharmaceuticals
- Target Recruit Count
- 375
- Registration Number
- NCT00115089